BMS22 is a novel competitive CCR2 antagonist. References: Auvynet C, Baudesson de Chanville C, Hermand P, Dorgham K, Piesse C, Pouchy C, Carlier L, Poupel L, Barthélémy S, Felouzis V, Lacombe C, Sagan S, Salomon B, Deterre P, Sennlaub F, Combadière C. ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration. FASEB J. 2016 Jun;30(6):2370-81. doi: 10.1096/fj.201500116. Epub 2016 Mar 15. PubMed PMID: 26979087.

纯度：≥98%

CAS：445479-97-0